Question 1 – In the past three months, how many patients were treated for Triple-Negative Breast Cancer with the following:
a) Anthracycline (e.g. doxorubicin) as a single agent
b) Atezolizumab + nab-paclitaxel or paclitaxel
c) Capecitabine as a single agent
d) Eribulin as a single agent
e) Eribulin + other chemotherapy
f) PARP inhibitor (e.g. Olaparib)
g) Platinum (e.g. carboplatin, cisplatin) as a single agent
h) Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
i) Other single agent chemotherapy
j) Other chemotherapy combination
k) Other immunotherapy containing regimen
l) Other active systemic anti-cancer therapy
Question 2 – How many of these Triple-Negative Breast Cancer patients treated in the last three months received treatment that was:
a) Privately funded
b) Part of clinical trial
c) Part of an early access scheme

Download response Triple-Negative Breast Cancer. 261021.docx